12:00 AM
 | 
Jun 03, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

NGR-hTNF: Additional Phase II data

Additional data from the open-label, Italian Phase II NGR014 trial in 121 chemotherapy-naïve patients with stage IIIb/IV NSCLC showed that 0.8 µg/m 2 NGR-hTNF every 3 weeks plus cisplatin and pemetrexed or gemcitabine led to similar median PFS (5.8 vs. 5.6 months), response rates (25% vs. 21%) and 1-year OS rate (53% vs....

Read the full 244 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >